GSK RSV shot 43% effective against severe disease in third year
WEB20 hours ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK presents positive data for AREXVY, its respiratory syncytial …
WEB1 day ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB20 hours ago · 1:42. GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. The shot for older adults showed cumulative efficacy ...
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker...
Press releases | GSK US
WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK raises profit outlook on strong vaccine, HIV drug sales
WEBMay 1, 2024 · GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
GSK posts blowout RSV vaccine sales, raises outlook - CNBC
WEBJan 31, 2024 · GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked...
New GSK to deliver step-change in growth and performance over …
WEBJun 23, 2021 · At an update to investors today, GlaxoSmithKline plc (GSK LSE & NYSE) will provide details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business.